for Genetic hearing loss
FDA approved Regeneron's Otarmeni (lunsotogene parvec-cwha), the first-ever gene therapy treatment for genetic hearing loss, under the FDA Commissioner's National Priority Voucher (CNPV) pilot program.
Otarmeni is a gene therapy designed to deliver a functional copy of a specific gene directly into the inner ear. This approach aims to address the root genetic cause of hearing loss by potentially restoring the function of hair cells in the cochlea. For individuals with this inherited condition, the treatment could offer a way to improve hearing and reduce the associated social and developmental challenges.